XEL:NASDAQXcel Energy Inc. Analysis
Data as of 2026-05-11 - not real-time
$79.39
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Xcel Energy (XEL) trades at $79.39, roughly four times its DCF‑derived fair value of $20.38, indicating a material overvaluation despite a modest 2.9% revenue growth and a forward‑PE of 17.5 that undercuts its trailing‑PE of 22.9. Dividend yield remains attractive at 2.99% with a 66% payout ratio, but free cash flow is deeply negative (-$7.47 B) and the balance sheet is leveraged (debt‑to‑equity ~165), raising sustainability concerns.
Technical signals are mixed: the 20‑day SMA (80.17) sits just below the current price, while the 50‑day SMA (80.48) is marginally above, creating a neutral bias. RSI at 46 and a bearish MACD histogram suggest limited upside momentum, and the stock hovers near its support of $77.35 with resistance at $83.85. Analyst sentiment skews strongly positive ("strong_buy"), yet the extreme‑greed market tone (FGI 90.73) and 24% 30‑day volatility underscore heightened short‑term risk.
Technical signals are mixed: the 20‑day SMA (80.17) sits just below the current price, while the 50‑day SMA (80.48) is marginally above, creating a neutral bias. RSI at 46 and a bearish MACD histogram suggest limited upside momentum, and the stock hovers near its support of $77.35 with resistance at $83.85. Analyst sentiment skews strongly positive ("strong_buy"), yet the extreme‑greed market tone (FGI 90.73) and 24% 30‑day volatility underscore heightened short‑term risk.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bearish MACD
- Strong dividend yield but sustainability concerns
- Analyst consensus bullish but valuation gap wide
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Stable regulated revenue base
- Elevated debt levels limiting growth flexibility
- Modest forward earnings growth versus high current price
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Significant overvaluation relative to DCF fair value
- Negative free cash flow and high leverage
- Potential regulatory and capital‑expenditure headwinds
Key Metrics & Analysis
Financial Health
Revenue Growth2.90%
Profit Margin14.14%
P/E Ratio22.9
ROE9.59%
ROA2.34%
Debt/Equity164.84
P/B Ratio2.1
Op. Cash Flow$4.8B
Free Cash Flow$-7471625216
Industry P/E21.7
Technical Analysis
TrendNeutral
RSI46.0
Support$77.35
Resistance$83.85
MA 20$80.17
MA 50$80.48
MA 200$77.62
MACDBearish
VolumeStable
Fear & Greed Index90.73
Valuation
Fair Value$20.38
Target Price$92.22
Upside/Downside16.16%
GradeOvervalued
TypeValue
Dividend Yield2.99%
Risk Assessment
Beta0.06
Volatility24.06%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.